A Known Technique for Showing a Motivation to Combine References
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Justin J. Gillett & Eric Wittgrove
INTEL CORP. V. PACT XPP SCHWEIZ AG
Before Newman, Prost, and Hughes. Appeal from the Patent Trial and Appeal Board.
Summary: Under the “known-techniques” rationale, a motivation to combine two prior art references exists when the references address the same problem and one of the references provides a known technique that would suitably address that problem.
Intel petitioned for Inter Partes Review of Pact’s patent directed to computer memory access. Pact argued that Intel failed to demonstrate a motivation to combine two asserted references. Intel argued a motivation to combine existed using the “known-technique” rationale: the two references related to the same field and addressed the same problem, and the second reference provided a known technique that would suitably address that problem. The PTAB rejected Intel’s argument and upheld the patentability of the petitioned claim. The PTAB reasoned that there was no motivation to use the known technique of the second reference because the first reference already addressed the problem. Thus, the PTAB concluded that using the technique of the second reference would not improve the teaching of the first. Intel appealed.
On appeal, the Federal Circuit reversed and remanded. It specified that the known technique of the second reference need not categorically improve the teaching of the first; the combination need not be “the best option, only [] a suitable option.” The Federal Circuit concluded that the PTAB’s reasoning “belies its conclusion”: the fact that the two references “address the same problem and that [the technique of the second reference] was a known way to address that problem is precisely the reason that there’s a motivation to combine.”
Editor: Paul Stewart
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…